Absci Corporation (ABSI) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 2 Margin 1 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

10
ABSI (Absci) Q2 2026: $100M Financing and Positive Phase 1 Data Propel Prolactin Receptor Franchise Toward Key Milestones
August 12, 2026
9
Abcide (ABSI) Q1 2026: $25B AGA TAM Targeted as ABS-201 Pipeline Expands Beyond Hair Loss
May 08, 2026
10
Absci (ABSI) Q4 2025: ABS-201 Addresses $25B AGA Market as Phase 1-2A Safety Holds
March 25, 2026
8
AbSci (ABSI) Q3 2025: $35M Cash Jump Extends Runway as ABS-201 Dual Indication Strategy Takes Center Stage
November 13, 2025
12
Abcide (ABSI) Q2 2025: $64M Capital Raise Extends Runway, Puts ABS-201 on Accelerated Path
August 12, 2025
12
AbSci (ABSI) Q1 2025: ABS-101 Enters Clinic, Unlocking First-in-Human Milestone
July 06, 2025
13
Absci Corporation (ABSI) Q4 2024: $20M AMD Investment Accelerates AI-Driven Antibody Innovation and Clinical Pipeline Advancement
March 18, 2025
AbSci (ABSI) Q3 2024: $247M AstraZeneca Milestone Validates AI Platform, Internal Pipeline Targets H1 2025 Data
November 12, 2024
AbSci (ABSI) Q2 2024: MSK Partnership Adds Six Programs, Diversifies R&D Model
August 14, 2024
AbSci (ABSI) Q1 2024: $86M Raise Extends Runway, Accelerates Internal Pipeline Execution
May 14, 2024

Browse all companies